Natera, Inc. (NASDAQ:NTRA) Receives Consensus Recommendation of “Buy” from Analysts

Natera, Inc. (NASDAQ:NTRA) has received a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat Ratings reports. Fourteen analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $86.40.

Several research analysts have weighed in on NTRA shares. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research report on Friday, April 5th. Canaccord Genuity Group raised their price objective on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Piper Sandler raised their price objective on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Finally, Stephens restated an “overweight” rating and set a $78.00 price objective on shares of Natera in a research report on Tuesday, January 30th.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 14,813 shares of Natera stock in a transaction on Monday, January 29th. The shares were sold at an average price of $65.09, for a total value of $964,178.17. Following the completion of the transaction, the chief executive officer now directly owns 246,957 shares of the company’s stock, valued at approximately $16,074,431.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Solomon Moshkevich sold 80,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the sale, the insider now owns 117,560 shares in the company, valued at approximately $10,676,799.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 14,813 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $65.09, for a total transaction of $964,178.17. Following the completion of the sale, the chief executive officer now owns 246,957 shares of the company’s stock, valued at approximately $16,074,431.13. The disclosure for this sale can be found here. Insiders sold 448,782 shares of company stock valued at $36,150,651 in the last three months. Corporate insiders own 9.42% of the company’s stock.

Institutional Investors Weigh In On Natera

Several institutional investors have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Natera in the 1st quarter worth about $2,606,000. Maryland State Retirement & Pension System lifted its holdings in Natera by 11.2% during the 1st quarter. Maryland State Retirement & Pension System now owns 8,535 shares of the medical research company’s stock valued at $761,000 after buying an additional 857 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in Natera during the 1st quarter valued at about $33,956,000. Allspring Global Investments Holdings LLC lifted its holdings in Natera by 19.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock valued at $78,967,000 after buying an additional 143,246 shares in the last quarter. Finally, LVW Advisors LLC bought a new stake in Natera during the 1st quarter valued at about $209,000. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $88.61 on Tuesday. The stock has a market cap of $10.70 billion, a PE ratio of -23.38 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. Natera has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The firm’s 50-day simple moving average is $86.40 and its two-hundred day simple moving average is $66.49.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Analysts anticipate that Natera will post -2.35 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.